You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
If approved, the kit would enable automated sample preparation for the company's T-SPOT.TB test using blood samples stored up to 54 hours at room temperature.
The firm's revenues in Asia were up compared to a year ago, but the coronavirus pandemic drove down revenues in the US, Europe, and the rest of the world.
The company's CEO said that its single-molecule tethering technology has demonstrated limits of detection comparable to commercial molecular tests.
The company's Q3 sales reflect ongoing demand for COVID-19 testing products and improved customer demand in other areas of the firm's portfolio.
The option was exercised under a multiyear contract between T2 Bio and BARDA valued at a total of $69 million if all options are exercised.
The single-visit blood test is one of two FDA-cleared alternatives to the traditional tuberculin skin test, according to Oxford Immunotec.
The money will be used for research and development, building a clinical laboratory network, and seeking regulatory approval.
On an adjusted basis at constant exchange rates, revenues grew 19 percent year over year, in line with guidance provided by the company in early July.
Oxford Immunotec said that a decrease in revenues for its US business was partly driven by the impact of planned inventory destocking by Quest Diagnostics.
National TB control programs may now order the T-spot.TB, a blood test for TB screening, through the Stop TB Partnership - GDF procurement mechanism.